Biotechnology

Kodiak Sciences

Kodiak Sciences released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9401 (forecast USD -1.0114)

Kodiak Sciences Announces Q1 2026 Financial Results

Kodiak Sciences Reports Q1 2026 Net Loss, Zenkuda's Clinical Trial Shows Positive Results

Kodiak Sciences Releases Clinical Data on KSI-101 for Macular Edema Treatment

JPMorgan Analyst Reiterates Buy Rating on Kodiak Sciences

HC Wainwright Downgrades Kodiak Sciences EPS Forecast

Kodiak Sciences CFO Disposes of 30,000 Shares

Kodiak Sciences released FY2025 Q4 earnings on March 31 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.0423 (forecast USD -1.0377)

Kodiak Sciences released FY2025 earnings on March 31 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.322 (forecast USD -4.239)

Kodiak Sciences Announces Positive Third-Stage Results for Diabetic Retinopathy Drug Zenkuda

Kodiak Sciences Inc. Sees Significant Increase in Short Interest

Kodiak Sciences Inc. to Speak at the 44th J.P. Morgan Healthcare Conference

Kodiak Sciences Announces $160 Million Equity Financing

H.C. Wainwright Reiterates Kodiak Sciences Buy Rating, Raises Price Target to $26

Kodiak Sciences released FY2025 9 Months earnings on November 13 (EST), actual revenue USD 0, actual EPS USD -3.281

Kodiak Sciences released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.1626 (forecast USD -1.0319)

Kodiak Sciences Earns Buy Rating Based on KSI-101 Drug

JPMorgan Raises Kodiak Sciences Rating to 'Overweight' and Raises Target Price

Barclays Upgrades Kodiak Sciences' Stock Rating and Price Target

Kodiak Sciences released FY2025 Semi-Annual earnings on August 13 (EST) with actual revenue of USD 0 and EPS of USD -2.1184

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

Kodiak Sciences (NasdaqGM:KOD) announced positive Phase 3 GLOW2 results for Zenkuda in diabetic retinopathy, supporting a potential multi-indication BLA submission. The stock is currently trading at $43.68, with a year-to-date increase of 67.9%. Analysts have a consensus target of $56.33, indicating potential upside. However, Kodiak faces funding risks with less than a year of cash runway and under $1 million in revenue. Investors should monitor BLA submission timing and share price movements relative to analyst targets.

Simplywall

Kodiak Sciences Zenkuda Data Shifts Focus To Retinal Pipeline Value

LifeSci Capital analyst Patrick Dolezal has maintained a Buy rating on Kodiak Sciences (KOD) with a price target of $65.00. Dolezal, a 5-star analyst with a 45.41% success rate, reports an average return of 17.4%. The consensus among analysts for Kodiak Sciences is a Strong Buy, with an average price target of $63.80.

Tip Ranks

iBio

Rocket Pharma

ROCKET PHARMACEUTICALS INC C/WTS 02/09/2026 (TO PUR COM)

LifeSci Capital Remains a Buy on Kodiak Sciences (KOD)

Earnings Watch

Kodiak Sciences | 8-K: FY2026 Q1 Revenue: USD 0

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results | KOD Stock News

StockTitan

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results | KOD Stock News

Kodiak Sciences is presenting new clinical data for its bispecific eye therapy KSI-101, showing positive results from Phase 1b MESI cohorts in Asia that align with U.S. APEX outcomes. This supports the company's Phase 3 development plans. However, despite the encouraging data, concerns about funding and execution risks remain, with shares potentially trading above fair value. Analysts have varying fair value estimates for the stock, highlighting the need for careful evaluation of both scientific progress and financial health.

Will Positive Asian MESI Data and Phase 3 Expansion Reshape Kodiak Sciences' (KOD) Eye-Drug Narrative?

RIA Advisory Group LLC has reduced its stake in Kodiak Sciences Inc. (NASDAQ:KOD) by 31.9% in Q4, now holding 113,473 shares. Other institutional investors have also adjusted their positions, with notable new investments from GF Fund Management and Mirae Asset Global Investments. Kodiak Sciences' stock opened at $43.96, with a market cap of $2.73 billion. The company reported a loss of $1.04 EPS for the last quarter, missing estimates. Analysts have mixed ratings, with an average target price of $35.43 and a "Moderate Buy" rating.

Market Beat

Kodiak Sciences Inc. $KOD Stock Holdings Decreased by RIA Advisory Group LLC

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences | KOD Stock News

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences | KOD Stock News

Kodiak Sciences(KOD.US)

Kodiak Sciences Zenkuda Data Shifts Focus To Retinal Pipeline Value

LifeSci Capital Remains a Buy on Kodiak Sciences (KOD)

Kodiak Sciences | 8-K: FY2026 Q1 Revenue: USD 0

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results | KOD Stock News

Will Positive Asian MESI Data and Phase 3 Expansion Reshape Kodiak Sciences' (KOD) Eye-Drug Narrative?

Kodiak Sciences Inc. $KOD Stock Holdings Decreased by RIA Advisory Group LLC

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences | KOD Stock News